Zacks Investment Research

Selected news for Zacks Investment Research, representing 1% of data collected since 10/2017. Recent stories appear in techknowbits.com and Dakota Financial News. This capital firm shares healthcare news with Inovalon, BioTelemetry, iRhythm, Teladoc, Medidata Solutions and hundreds of others.

Please provide a valid email address.

Selected Headines

Date Headline (link) Source Relevant Snippet
1/6/2021 NeoGenomics, Inc. (NASDAQ:NEO) Expected to Post Quarterly Sales of $124.66 Million The Markets Daily ... with estimates ranging from $441.70 million to $449.00 million. For the next financial year, analysts expect that the company will post sales of $535.17 million, with estimates ranging from $523.01 million to $551.98 million. Zacks Investment Research ’s sales averages are an average based on a survey of sell-side research firms that follow NeoGenomics. Get NeoGenomics alerts:NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, October 27th ...
1/5/2021 Analysts Set Encompass Health Co. (AMEX:EHC) Target Price at $89.00 thelincolnianonline.com ... 30th. Barclays upgraded shares of Encompass Health from an “equal weight” rating to an “overweight” rating and set a $96.00 target price on the stock in a report on Monday, November 23rd. Zacks Investment Research upgraded shares of Encompass Health from a “sell” rating to a “hold” rating and set a $87.00 price target on the stock in a report on Wednesday, December 30th. Finally, Credit ...
1/4/2021 $124.66 Million in Sales Expected for NeoGenomics, Inc. (NASDAQ:NEO) This Quarter Mayfield Recorder 124.66 Million in Sales Expected for NeoGenomics, Inc. (NASDAQ:NEO) This Quarter Posted by Clark Linder on Jan 3rd, 2021Analysts expect NeoGenomics, Inc. (NASDAQ:NEO) to announce sales of $124.66 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for NeoGenomics’ earnings, with the lowest sales estimate coming in at $123.25 million and the highest estimate coming in at $125.40 million. NeoGenomics ...
1/4/2021 Homology Medicines, Inc. (NASDAQ:FIXX) Given Consensus Rating of “Buy” by Analysts Mayfield Recorder ... number of analysts have issued reports on FIXX shares. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Homology Medicines in a report on Monday, December 14th. Zacks Investment Research upgraded shares of Homology Medicines from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Tuesday, December 22nd. Finally ...
1/4/2021 Zacks: Analysts Expect Haemonetics Co. (NYSE:HAE) Will Post Quarterly Sales of $225.08 Million zolmax.com ... year, with estimates ranging from $842.57 million to $867.37 million. For the next year, analysts forecast that the company will report sales of $972.68 million, with estimates ranging from $921.26 million to $1.02 billion. Zacks Investment Research ’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Haemonetics. Get Haemonetics alerts:Haemonetics (NYSE:HAE) last announced its quarterly earnings ...
1/4/2021 HealthEquity, Inc. (NASDAQ:HQY) Expected to Post Earnings of $0.32 Per Share zolmax.com ... current year, with EPS estimates ranging from $1.51 to $1.61. For the next year, analysts expect that the company will report earnings of $1.67 per share, with EPS estimates ranging from $1.39 to $1.80. Zacks Investment Research ’s EPS calculations are an average based on a survey of research analysts that cover HealthEquity. Get HealthEquity alerts:HealthEquity (NASDAQ:HQY) last posted its quarterly earnings data on Sunday, December 6th. The ...
1/4/2021 Brokerages Anticipate Illumina, Inc. (NASDAQ:ILMN) Will Announce Quarterly Sales of $870.10 Million Mayfield Recorder ... year, with estimates ranging from $3.14 billion to $3.17 billion. For the next year, analysts anticipate that the company will report sales of $4.02 billion, with estimates ranging from $3.94 billion to $4.13 billion. Zacks Investment Research ’s sales averages are a mean average based on a survey of analysts that that provide coverage for Illumina. Get Illumina alerts:Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, October ...
1/4/2021 Illumina (NASDAQ:ILMN) Rating Lowered to Buy at BidaskClub rivertonroll.com ... NASDAQ:ILMN) from a strong-buy rating to a buy rating in a research report sent to investors on Thursday morning, BidAskClub reports.Several other research firms have also recently issued reports on ILMN. Zacks Investment Research cut Illumina from a hold rating to a sell rating and set a $351.00 price objective for the company. in a research report on Wednesday, December 2nd. Piper Sandler upgraded shares of Illumina ...
1/3/2021 Tapestry (NYSE:TPR) Price Target Increased to $35.00 by Analysts at Guggenheim Daily Political Encompass Health (AMEX:EHC) Upgraded to Hold at Zacks Investment Research Tapestry (NYSE:TPR) Price Target Increased to $35.00 by Analysts at Guggenheim January 2nd, 2021 - Comments Off on Tapestry (NYSE:TPR) Price Target Increased to $35.00 by Analysts at Guggenheim - Filed Under - by Latisha Jones TweetTapestry (NYSE:TPR) had its price target increased by Guggenheim from $27.00 to $35.00 in a report issued on Wednesday, The Fly reports ...
1/3/2021 BidaskClub Lowers US Foods (NYSE:USFD) to Hold Daily Political Encompass Health (AMEX:EHC) Upgraded to Hold at Zacks Investment Research BidaskClub Lowers US Foods (NYSE:USFD) to Hold January 2nd, 2021 - Comments Off on BidaskClub Lowers US Foods (NYSE:USFD) to Hold - Filed Under - by Stacy Sanders TweetBidaskClub lowered shares of US Foods (NYSE:USFD) from a buy rating to a hold rating in a research note released on Thursday, BidAskClub reports.Several other equities analysts also recently ...
1/3/2021 Bicycle Therapeutics (NASDAQ:BCYC) Stock Rating Lowered by BidaskClub Daily Political Encompass Health (AMEX:EHC) Upgraded to Hold at Zacks Investment Research Bicycle Therapeutics (NASDAQ:BCYC) Stock Rating Lowered by BidaskClub January 2nd, 2021 - Comments Off on Bicycle Therapeutics (NASDAQ:BCYC) Stock Rating Lowered by BidaskClub - Filed Under - by Trevor Kearing TweetBicycle Therapeutics (NASDAQ:BCYC) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and ...
1/3/2021 Westlake Chemical (NYSE:WLK) Downgraded to Hold at BidaskClub Daily Political Encompass Health (AMEX:EHC) Upgraded to Hold at Zacks Investment Research Westlake Chemical (NYSE:WLK) Downgraded to Hold at BidaskClub January 2nd, 2021 - Comments Off on Westlake Chemical (NYSE:WLK) Downgraded to Hold at BidaskClub - Filed Under - by Tyrone Williams TweetBidaskClub downgraded shares of Westlake Chemical (NYSE:WLK) from a buy rating to a hold rating in a research report report published on Wednesday, BidAskClub reports.Other analysts also ...
1/3/2021 Jamf (NYSEARCA:JAMF) Upgraded to “Buy” at Zacks Investment Research Daily Political Encompass Health (AMEX:EHC) Upgraded to Hold at Zacks Investment Research Jamf (NYSEARCA:JAMF) Upgraded to “Buy” at Zacks Investment Research January 2nd, 2021 - Comments Off on Jamf (NYSEARCA:JAMF) Upgraded to “Buy” at Zacks Investment Research - Filed Under - by Trevor Kearing TweetZacks Investment Research upgraded shares of Jamf (NYSEARCA:JAMF) from a hold rating to a buy rating in a research note issued to investors on ...
1/3/2021 Zacks: Brokerages Anticipate Yelp Inc. (NYSE:YELP) Will Announce Quarterly Sales of $227.39 Million Daily Political ... year, with estimates ranging from $860.60 million to $870.15 million. For the next year, analysts forecast that the firm will report sales of $957.11 million, with estimates ranging from $935.83 million to $980.37 million. Zacks Investment Research ’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Yelp. Get Yelp alerts:Yelp (NYSE:YELP) last posted its earnings results on Thursday ...
1/3/2021 Becton, Dickinson and Company (NYSE:BDX) Expected to Announce Quarterly Sales of $4.72 Billion Mayfield Recorder ... 4.72 Billion Posted by Frank Smitson on Jan 3rd, 2021Equities research analysts expect that Becton, Dickinson and Company (NYSE:BDX) will report $4.72 billion in sales for the current fiscal quarter, according to Zacks Investment Research . Eight analysts have issued estimates for Becton, Dickinson and’s earnings. The lowest sales estimate is $4.60 billion and the highest is $4.77 billion. Becton, Dickinson and posted sales of $4.23 billion during ...